Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Better Therapeutics, Inc. BTTX

Healthcare  —  Biotechnology
0.00 0.00 NaN as of 25 Sep
Market cap
$850.0K
P/E
0.0×
Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Better Therapeutics, Inc. (BTTX) Business Profile

Updated before January 2025

Company Overview

Better Therapeutics, Inc. (BTTX) is a pioneering digital therapeutics company that focuses on developing prescription digital therapeutics (PDTs) to treat chronic diseases. Founded in 2015 and headquartered in San Francisco, California, BTTX leverages cognitive behavioral therapy (CBT) and other evidence-based interventions to address the root causes of chronic conditions. The company was co-founded by Kevin Appelbaum and David Perry, both of whom have extensive experience in healthcare and technology. Kevin Appelbaum serves as the CEO, bringing a wealth of expertise in scaling innovative healthcare solutions. The leadership team also includes other seasoned professionals with backgrounds in medicine, technology, and business strategy, ensuring a multidisciplinary approach to tackling healthcare challenges.

Core Business Segments

Prescription Digital Therapeutics (PDTs)

BTTX specializes in developing PDTs, which are software-based treatments prescribed by healthcare providers. These therapeutics are designed to complement or replace traditional pharmacological treatments. Key products include:

  • BT-001: A flagship product targeting type 2 diabetes by addressing behavioral and lifestyle factors contributing to the disease. BT-001 uses CBT to help patients adopt healthier habits and improve glycemic control.
  • Pipeline Products: BTTX is actively developing PDTs for other chronic conditions, including hypertension, hyperlipidemia, and non-alcoholic fatty liver disease (NAFLD).

Behavioral Health Solutions

BTTX integrates behavioral health interventions into its PDTs, focusing on modifying unhealthy behaviors that contribute to chronic diseases. These solutions are grounded in clinical evidence and aim to provide long-term health benefits.

Data-Driven Insights

The company also offers data analytics and insights to healthcare providers and payers. By analyzing patient data, BTTX helps stakeholders understand treatment efficacy and optimize care pathways.

Business Model

BTTX operates on a B2B2C (business-to-business-to-consumer) model. The company partners with healthcare providers, payers, and employers to deliver its PDTs to patients. Revenue is generated through:

  • Prescription Sales: PDTs are prescribed by healthcare providers and reimbursed by insurance companies.
  • Partnership Agreements: Collaborations with pharmaceutical companies and healthcare systems to integrate PDTs into existing treatment protocols.
  • Data Licensing: Monetizing anonymized patient data and insights to improve healthcare outcomes and inform future product development.

Strategic Direction

BTTX is committed to expanding its portfolio of PDTs to address a broader range of chronic conditions. Key strategic initiatives include:

  • Product Development: Accelerating the development of PDTs for hypertension, hyperlipidemia, and NAFLD.
  • Regulatory Approvals: Securing FDA clearance for its pipeline products to ensure widespread adoption.
  • Global Expansion: Exploring opportunities to enter international markets, particularly in regions with high prevalence of chronic diseases.
  • Sustainability Goals: Incorporating environmentally sustainable practices in product development and operations.
  • Technology Integration: Leveraging artificial intelligence and machine learning to enhance the efficacy of its PDTs.

Competitive Landscape

BTTX operates in a competitive market that includes both traditional pharmaceutical companies and emerging digital health startups. Key competitors include:

  • Pear Therapeutics: A leader in PDTs with a focus on substance use disorders and mental health.
  • Omada Health: Specializes in digital health programs for chronic disease management.
  • Livongo (now part of Teladoc Health): Offers digital solutions for diabetes and other chronic conditions.
  • Click Therapeutics: Develops PDTs for a range of indications, including depression and smoking cessation.

Despite the competition, BTTX differentiates itself through its focus on CBT-based interventions and its robust clinical evidence.

Risk Factors

BTTX faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: Delays in FDA approvals could hinder product launches.
  • Market Adoption: Resistance from healthcare providers and patients to adopt digital therapeutics.
  • Reimbursement Issues: Dependence on insurance companies for reimbursement could pose financial risks.
  • Supply Chain Disruptions: Although primarily a software company, any disruptions in technology infrastructure could affect service delivery.
  • Competition: Intense competition from both established players and new entrants in the digital health space.

Recent Developments

  • FDA Submission for BT-001: BTTX recently submitted BT-001 for FDA approval, marking a significant milestone in its journey.
  • Clinical Trials: The company completed a pivotal clinical trial for BT-001, demonstrating its efficacy in improving glycemic control in patients with type 2 diabetes.
  • Partnerships: BTTX announced collaborations with leading healthcare systems to pilot its PDTs.
  • Funding: The company secured additional funding to accelerate product development and expand its market reach.

Investment Considerations

Strengths

  • Innovative Product Portfolio: Focus on PDTs positions BTTX as a leader in the digital therapeutics space.
  • Clinical Evidence: Strong clinical data supporting the efficacy of its products.
  • Experienced Leadership: A seasoned team with expertise in healthcare and technology.
  • Market Potential: Growing demand for non-pharmacological treatments for chronic diseases.

Risks

  • Regulatory Hurdles: Dependence on FDA approvals for product launches.
  • Market Acceptance: Uncertainty around the adoption of digital therapeutics by healthcare providers and patients.
  • Financial Performance: As a relatively young company, BTTX may face challenges in achieving profitability.

Conclusion

Better Therapeutics, Inc. is at the forefront of the digital therapeutics revolution, offering innovative solutions to address the root causes of chronic diseases. With a strong product pipeline, robust clinical evidence, and a clear strategic vision, BTTX is well-positioned to capitalize on the growing demand for digital health solutions. However, investors should carefully consider the regulatory and market risks associated with this emerging sector. Overall, BTTX represents a compelling opportunity for those looking to invest in the future of healthcare.